



ASX ANNOUNCEMENT

Lumos and Burnet Diagnostics Initiative progress new point-of-care test for use in monitoring liver health in coming clinical trial.

Key Highlights

- Extension of agreement with the Burnet Diagnostics Initiative to manufacture a lateral flow test developed at the BDI and develop and manufacture customised Lumos readers to monitor liver function in an upcoming clinical trial.
- The point-of-care test will provide rapid, near-patient measurement of blood levels of the liver biomarker, Alanine Transaminase (ALT) that when elevated can indicate liver injury, possibly from a drug reaction.
- The ALT point-of-care test builds on feasibility work conducted in 2023, to develop a point-of-care prototype for evaluation of clinical specimens.
- Lumos will provide development, regulatory and manufacturing services to BDI over the next 9-12 months, generating fees between US\$0.7 million and US\$1.0 million.

MELBOURNE, Australia (26 August 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies is pleased to announce an extension of its existing agreement with the Burnet Diagnostics Initiative (BDI) to produce Alanine Transaminase (ALT) lateral flow tests, customised Lumos readers and a mobile phone application for use in an upcoming US based clinical trial.

This project marks the continuation of the feasibility studies conducted in 2023 to generate a prototype ALT test for evaluation with clinical specimens.

The new phase of collaboration is set to commence in August 2024 and will specifically support the production of the BDI point-of-care ALT testing system for use by healthcare professionals with high-risk patients undergoing routine liver function monitoring. High levels of ALT in the blood can indicate liver injury, possibly from a drug reaction. A point-of-care ALT test can provide rapid on-site results allowing faster detection of acute liver toxicity caused by adverse drug reactions, enabling clinicians to act swiftly

to address any liver concerns. Results from the BDI ALT test clinical trial will be used to collect real-world data to guide future product development efforts, including a home based, self-test format.

As part of this engagement, Lumos will perform development, regulatory and manufacturing services over the next 9-12 months, generating fees between US\$0.7 million and US\$1.0 million. Should this project prove successful, Lumos anticipates further supporting the BDI in the next phase of trials and regulatory submissions.

“We are proud to announce this extension of our partnership with BDI, solidifying our strong relationship built on previous successful collaborations,” said Doug Ward, CEO of Lumos. “This contract win emphasizes Lumos’ capabilities and provides another opportunity to utilize our reader and the application of intellectual property to address critical unmet clinical needs in the diagnostics arena. We are committed to enhancing the landscape of point-of-care testing and are excited about the possibilities this project holds.”

Jennifer Barnes, CEO of the Burnet Diagnostics Initiative, stated, “Our ongoing collaboration with Lumos is a testament to the synergy between our organizations. Together, we are working towards innovative solutions that will ultimately improve patient outcomes. We appreciate Lumos’ dedication and expertise in developing and manufacturing accessible, rapid diagnostic technologies. Having a trusted manufacturing partner is key to the BDI rapidly translating our diagnostic innovations.”

Lumos Diagnostics looks forward to further developing its relationship with the Burnet Diagnostics Initiative and contributing to advancements in clinical diagnostics.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About Burnet Diagnostics Initiative

The Burnet Diagnostics Initiative (BDI) is a commitment by the Burnet Institute to develop the systems, resources and processes to support diagnostic product development and enhance translation of its point-of-care diagnostics research into practical health solutions. The BDI has built capacity in Melbourne for its internal research and product development, and for engagement with the In Vitro Diagnostics (IVD) industry through strategic partnerships.

For more information visit burnet.edu.au.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^ACK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598